

**Supplemental Table S1.** Clinical Characteristics of Patients in No Overt Hypothyroidism Group According to the Recovery of Thyroid Dysfunction ( $n=139$ )

Characteristic	Recovery ( $n=84$ )	No recovery ( $n=55$ )	<i>P</i> value
Age, yr	65.9±11.4	66.0±11.3	0.940
Female sex	22 (26.2)	18 (32.7)	0.405
PD-1/PD-L1 inhibitor			0.298
Pembrolizumab	36 (42.9)	22 (40.0)	
Nivolumb	33 (39.3)	19 (34.5)	
Durvalumab	4 (4.8)	2 (3.6)	
Atezolizumab	11 (13.1)	12 (21.8)	
Duration of PD-1/PD-L1 inhibitor therapy, mo	6.0 (2.0–12.0)	2.0 (1.0–5.0)	<0.001
No. of doses of PD-1/PD-L1 inhibitor	9.0 (4.0–17.0)	5.0 (3.0–9.0)	0.001
Baseline TSH level	2.23±1.37	2.62±1.54	0.138
Baseline free T4 level	1.24±0.18	1.22±0.18	0.626
The last thyroid function status			<0.001
Normal	84 (100.0)	0	
Subclinical hypothyroidism	-	42 (76.4)	
Subclinical hyperthyroidism	-	6 (10.9)	
Overt hyperthyroidism	-	7 (12.7) <sup>a</sup>	

Values are expressed as mean±standard deviation, number (%), or median (interquartile range).

PD-1, programmed cell death protein-1; PD-L1, programmed cell death protein-ligand 1; TSH, thyroid stimulating hormone; T4, thyroxine.

<sup>a</sup>All patients ( $n=7$ ) were negative for TSH binding inhibitory immunoglobulin.